Pavlo Kot

Neumora Therapeutics advances NMRA-215 NLRP3 inhibitor in obesity drug development

Neumora Therapeutics advances NMRA-215 NLRP3 inhibitor in obesity drug development
Neumora updates on NMRA-215

Neumora Therapeutics has presented new data on NMRA-215, an oral NLRP3 inhibitor in the company pipeline for obesity treatment. The compound is noted for its high brain penetration and is currently under development for obesity indications.

The update was provided during the companys poster presentation at ObesityWeek, highlighting the ongoing progress in Neumora Therapeutics drug research for obesity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.